3-羟基-3-甲基丁腈 | 13635-04-6

• 物质功能分类: 有机原料 - 腈类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-羟基-3-甲基丁腈
• 中文别名: β-羟基异戊腈；Β-羟基异戊腈
• 英文名称: 3-hydroxy-3-methylbutyronitrile
• 英文别名: 3-hydroxy-3-methylbutanenitrile；2-cyano-1,1-dimethylethanol
• CAS: 13635-04-6
• 化学式: C₅H₉NO
• mdl: MFCD00043123
• 分子量: 99.1326
• InChiKey: CWPMDJFBWQJRGT-UHFFFAOYSA-N

物化性质

• 沸点：
  114-116 °C/30 mmHg (lit.)
• 密度：
  0.959 g/mL at 20 °C (lit.)
• 闪点：
  97 °C

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  44
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R20/22
• WGK Germany：
  3
• 海关编码：
  2926909090
• 危险品运输编号：
  UN 3276 6.1/PG 3
• 危险性防范说明：
  P261,P280,P301+P312,P304+P340
• 危险性描述：
  H302,H332
• 储存条件：
  储存条件为2-8°C，并需保存在惰性气体中。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 3-Hydroxy-3-methylbutyronitrile
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 13635-04-6

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Inhalation (Category 4), H332
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R20/22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
Harmful if swallowed.
Harmful if inhaled.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C5H9NO
Molecular Weight : 99,13 g/mol
CAS-No. : 13635-04-6
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
3-Hydroxy-3-methylbutyronitrile
Acute Tox. 4; H302, H332 -
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
3-Hydroxy-3-methylbutyronitrile
Xn, R20/22 -
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure adequate ventilation.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Recommended storage temperature: 2 - 8 °C
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator
with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup
to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: clear, liquid
Colour: light yellow
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and 114 - 116 °C at 40 hPa
boiling range
g) Flash point 97 °C - closed cup
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density 0,959 g/mL at 20 °C
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
no data available
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 3276 IMDG: 3276 IATA: 3276
UN proper shipping name
ADR/RID: NITRILES, TOXIC, LIQUID, N.O.S. (3-Hydroxy-3-methylbutyronitrile)
IMDG: NITRILES, TOXIC, LIQUID, N.O.S. (3-Hydroxy-3-methylbutyronitrile)
IATA: Nitriles, liquid, toxic, n.o.s. (3-Hydroxy-3-methylbutyronitrile)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

该化合物3-羟基-3-甲基丁腈主要用于科研领域。

反应信息

• 作为反应物：
  描述：

  3-羟基-3-甲基丁腈 在 水 作用下， 以 aq. phosphate buffer 为溶剂， 反应 24.0h， 以26%的产率得到β-羟基异戊酸
  参考文献：
  名称：

  [EN] PROCESS FOR PREPARING 3-HYDROXY-3-METHYLBUTYRATE (HMB) AND SALTS THEREOF
  [FR] PROCÉDÉ DE PRÉPARATION DE 3-HYDROXY-3-MÉTHYLBUTYRATE (HMB) ET DE SELS DE CELUI-CI

  摘要：

  本发明涉及一种制备3-羟基-3-甲基丁酸酯（HMB）或其盐的方法，所述方法包括（a）将异丁烯氧化物与氰化物反应，以获得3-羟基-3-甲基丁腈，以及（b）水解步骤（a）中获得的3-羟基-3-甲基丁腈，以获得HMB，其中水解步骤（b）使用至少一种腈酶酶或者使用至少一种腈水合酶和至少一种酰胺酶的组合来执行。

  公开号：

  WO2020200952A1
• 作为产物：
  描述：

  2-甲基-3-丁炔-2-醇 在 (1,4-dimethyl-5,7-diphenyl-1,2,3,4-tetrahydro-6H-cyclopenta[b]pyrazin-6-one)ruthenium tricarbonyl complex 、 一水合肼 作用下， 以 甲苯 为溶剂， 以91%的产率得到3-羟基-3-甲基丁腈
  参考文献：
  名称：

  从炔丙醇和肼中钌催化形成吡唑或 3-羟基腈

  摘要：

  官能化吡唑是在钌催化的级联过程中由仲丙醇和肼生成的，包括氧化还原异构化、迈克尔加成、环缩合和脱氢步骤。相同的双功能催化剂通过反马尔可夫尼科夫加氢胺化随后消除氨来介导炔丙醇叔醇与肼的转化为 3-羟基腈。

  DOI：

  10.24820/ark.5550190.p010.893

文献信息

• [EN] THERAPEUTIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET LEURS UTILISATIONS
  申请人：GENENTECH INC

  公开号：WO2016123391A1

  公开（公告）日：2016-08-04

  The present invention relates to compounds of formula (I): and to salts thereof, wherein R1-R6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.

  本发明涉及式(I)的化合物及其盐，其中R1-R6具有规范中定义的任何值，以及其组合物和用途。这些化合物可用作TAF1的抑制剂。还包括包含式(I)的化合物或其药学上可接受的盐的药物组合物，以及在治疗各种TAF1介导的疾病中使用这些化合物和盐的方法。
• DEUTERATED BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US20200017450A1

  公开（公告）日：2020-01-16

  The present invention relates to a medicament for treating or preventing a disease involving Na channel, for example, neuropathic pain, nociceptive pain, inflammatory pain, small-fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria, or multiple sclerosis, comprising a compound of formula (I) wherein R 1a , R 1b , R 1c , and R 1d are hydrogen, halogen, cyano, C 1-4 alkyl, C 1-4 alkoxy, etc., provided that at least one of R 1a , R 1b , R 1c and R 1d is the above C 6-10 aryl, C 6-10 aryloxy, etc., R 2 and R 3 are hydrogen, C 1-6 alkyl, C 3-10 cycloalkyl, etc., R 4 is hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, etc., m is 0, 1, or 2, L is CR 7 R 8 , R 7 and R 8 are hydrogen, hydroxy group, C 1-4 alkyl, C 1-4 alkoxy, etc., or a pharmaceutically acceptable salt thereof.

  该发明涉及一种用于治疗或预防涉及Na通道的疾病的药物，例如神经痛、伤害性疼痛、炎症性疼痛、小纤维神经病、红细胞增多症、阵发性极端疼痛障碍、排尿困难或多发性硬化等，包括式(I)的化合物，其中R1a、R1b、R1c和R1d为氢、卤素、氰基、C1-4烷基、C1-4烷氧基等，但至少其中一个为上述的C6-10芳基、C6-10芳氧基等，R2和R3为氢、C1-6烷基、C3-10环烷基等，R4为氢、C1-6烷基、C3-7环烷基等，m为0、1或2，L为CR7R8，R7和R8为氢、羟基、C1-4烷基、C1-4烷氧基等，或其药学上可接受的盐。
• [EN] 2,4-SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] PYRIMIDINES 2,4-SUBSTITUEES SERVANT D'INHIBITEURS DE CYSTEINE PROTEASE
  申请人：GLAXO GROUP LTD

  公开号：WO2006027211A1

  公开（公告）日：2006-03-16

  Substituted heteroaryl nitrile derivatives of Formula (I) processes for their preparation, pharmaceutical compositions comprising such compounds and use of the compounds as cysteine protease inhibitors are provided.

  提供了公式（I）的取代杂环亚硝基腈衍生物的制备方法，包括这些化合物的制药组合物以及将这些化合物用作半胱氨酸蛋白酶抑制剂的用途。
• Ring Opening of Epoxides with Acetone Cyanohydrin Catalyzed by Lanthanoid(III) Alkoxides
  作者：Hiroshi Ohno、Atsunori Mori、Shohei Inoue

  DOI：10.1246/cl.1993.975

  日期：1993.6

  Ring opening of epoxide and aziridine with acetone cyanohydrin is promoted by a catalytic amount of lanthanoid(III) alkoxide to provide β-hydroxy nitrile and β-amino nitrile, respectively.

  催化量的镧系元素(III)醇盐促进环氧化物和氮丙啶与丙酮氰醇的开环，分别提供β-羟基腈和β-氨基腈。
• [EN] NOVEL PHOSPHORAMIDITES<br/>[FR] NOUVELLES PHOSPHORAMIDITES
  申请人：ROCHE INNOVATION CT COPENHAGEN AS

  公开号：WO2020169696A1

  公开（公告）日：2020-08-27

  The invention relates to a compound of formula (II) wherein X, Y, R5, Rx, Ry and Nu are as defined in the description and in the claims. The compound of formula (II) can be used in the manufacture of medicaments.

  该发明涉及具有公式（II）的化合物，其中X、Y、R5、Rx、Ry和Nu如描述和索赔中所定义。公式（II）的化合物可用于制造药物。